Clinical trials: Double Incontinence
Urinary Bladder, Overactive
A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
The study is intended to test the efficacy, safety and tolerability of two doses of mirabegron against placebo to treat patients with symptoms of overactive bladder
- Trial name
- ARIES (NCT00662909)
- Testing
- Mirabegron
- Where
- 125 sites in United States, Canada
- Volunteers
- 2,149 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder
A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)
This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety, and tolerability of solabegron modified release low dose or high dose tablets…
- Trial name
- VEL-2001 (NCT03594058)
- Testing
- Solabegron modified release tablets, low dose, Solabegron modified release tablets, high dose
- Where
- 77 sites in United States
- Volunteers
- 1,413 people
- Sponsor
- Velicept Therapeutics, Inc.
Urinary Bladder, Overactive
A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients
To evaluate the efficacy and safety of solifenacin succinate (Vesicare) 5mg OD in subjects with overactive bladder compared to tolterodine wmg, bid
- Trial name
- NCT00368706
- Testing
- solifenacin succinate, tolterodine
- Where
- 4 sites in China
- Volunteers
- 246 people
- Sponsor
- Astellas Pharma Inc
Stress Urinary Incontinence
Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence
This study evaluates the efficacy and safety of Autologous Muscle Derived Cells for Urinary Sphincter Repair (AMDC-USR; generic name: iltamiocel) compared to a placebo in the reduction of stress incontinence episode frequency in…
- Trial name
- CELLEBRATE (NCT03104517)
- Testing
- AMDC-USR (iltamiocel)
- Where
- 21 sites in United States, United Kingdom
- Volunteers
- 96 people
- Sponsor
- Cook MyoSite
Overactive Bladder
Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder
The purpose of this study is to evaluate the change from baseline between the active and sham treatment groups in the treatment of urgency (urinary) incontinence episodes (leaks).
- Trial name
- Beacon (NCT01369485)
- Testing
- (VERV™ System)
- Where
- 14 sites in United States
- Volunteers
- 163 people
- Sponsor
- Ethicon Endo-Surgery
Urinary Incontinence
A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.
A study to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual OAB symptoms in men.
- Trial name
- VICTOR (NCT00333112)
- Testing
- solifenacin succinate, tamsulosin
- Where
- 74 sites in United States
- Volunteers
- 398 people
- Sponsor
- Astellas Pharma Inc
Urinary Bladder, Overactive
Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder
The study is intended to test efficacy, safety and tolerability of two doses of YM178 against placebo and tolterodine to treat patients with symptoms of over active bladder.
- Trial name
- Blossom (NCT01604928)
- Testing
- YM178, tolterodine
- Where
- 30 sites in Belgium, Czechia and 4 more
- Volunteers
- 260 people
- Sponsor
- Astellas Pharma Europe B.V.
Urinary Bladder, Overactive, Urinary Incontinence
Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence
This study will evaluate the efficacy and safety of onabotulinumtoxinA 100 U (BOTOX®), compared to placebo, when injected into the bladder using an alternative injection paradigm in reducing the number of daily urinary…
- Trial name
- LO-BOT (NCT03052764)
- Testing
- onabotulinumtoxinA
- Where
- 31 sites in United States
- Volunteers
- 120 people
- Sponsor
- Allergan
Urinary Bladder Diseases, Urinary Bladder Overactive
A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)
The purpose of this study was to see if adding a new type of medication recently approved to treat overactive bladder (mirabegron) to an antimuscarinic treatment (solifenacin) would be more effective in controlling incontinence…
- Conditions
- Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
- Trial name
- BESIDE (NCT01908829)
- Testing
- mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg
- Where
- 219 sites in United States, Armenia and 29 more
- Volunteers
- 2,174 people
- Sponsor
- Astellas Pharma Europe Ltd.
Urinary Incontinence
Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction
The primary objective of the trial is to evaluate the effect of tolterodine ER plus tamsulosin versus placebo on patient perception of overall treatment benefit in men who have frequency and urgency, with or without urinary urge…
- Trial name
- NCT00147654
- Testing
- Tolterodine ER 4 mg QD, Tamsulosin 0.4 mg QD
- Where
- 95 sites in United States
- Volunteers
- 830 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Stress Urinary Incontinence
A Phase 2, Randomized, Placebo-controlled, Double-blind Study of EG017 in Female Patients With Stress Urinary Incontinence
The purpose of this study is to determine whether EG017 is safe and effective in the treatment of stress urinary incontinence in postmenopausal women.
- Trial name
- NCT05674045
- Testing
- EG017 3mg, EG017 6mg
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Overactive Bladder, Urinary Incontinence
ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)
This study is designed to determine the efficacy of escalating doses of ELB245 versus placebo , when administered to patients with OAB and to compare the efficacy of escalating doses of ELB245 versus the standard treatment…
- Trial name
- NCT00439192
- Testing
- ELB245, Tolterodine
- Where
- 31 sites in Germany, Poland and 1 more
- Volunteers
- 275 people
- Sponsor
- elbion AG
Stress Urinary Incontinence
Efficacy of Magnetic Stimulation for Stress Urinary Incontinence
The aim of the study is to investigate the effects of QRS®-1010 PelviCenter in female patients with stress urinary incontinence.
- Trial name
- NCT01924728
- Testing
- Magnetic stimulation
- Where
- Malaysia
- Volunteers
- 120 people
- Sponsor
- QRS Asia Sdn Bhd
Overactive Bladder
A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)
This study is designed to evaluate the safety, tolerability, and efficacy of vibegron administered once daily in patients with OAB.
- Trial name
- Empowur (NCT03492281)
- Testing
- vibegron, Tolterodine Tartrate ER
- Where
- 215 sites in United States, Canada and 4 more
- Volunteers
- 1,530 people
- Sponsor
- Urovant Sciences GmbH
Overactive Bladder
A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency
This study is designed to assess the efficacy of a flexible dose regimen of fesoterodine on micturition related nocturnal urgency episodes.
- Trial name
- NCT00911937
- Testing
- Fesoterodine
- Where
- 112 sites in United States
- Volunteers
- 963 people
- Sponsor
- Pfizer
Incontinence
Study of Escalating Doses of NRL001 Given in Slow-release Rectal Suppositories of Different Weights
Studies investigating single doses of different NRL001 formulations showed formulation-dependent differences in exposure, even though they had similar effects on mean anal resting pressure (MARP).
- Trial name
- NCT00850590
- Testing
- NRL001
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Norgine
Stress Urinary Incontinence
Japanese Bridging Study of Autologous Muscle Derived Cells Compared to Placebo for Female Urinary Sphincter Repair(JPN1)
This is a confirmatory/bridging study to evaluate the efficacy and safety of Autologous Muscle Derived Cells for Urinary Sphincter Repair (AMDC-USR) compared with placebo in the treatment of stress urinary incontinence (SUI) in…
- Trial name
- JPN1 (NCT03997318)
- Testing
- AMDC-USR
- Sponsor
- Cook MyoSite
Overactive Bladder Syndrome
Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity
The purpose of this study is to assess the effects of AV608, a neurokinin 1 (NK-1) antagonist, in subjects with Idiopathic Detrusor Overactivity.
- Trial name
- NCT00335660
- Testing
- AV608
- Where
- 13 sites in Netherlands, United Kingdom
- Volunteers
- 62 people
- Sponsor
- Avera Pharmaceuticals
Overactive Bladder
A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder
This study is designed to assess the efficacy and safety of a flexible dose regimen of fesoterodine on urgency urinary incontinence (UUI) episodes in vulnerable elderly subjects with overactive bladder (OAB).
- Trial name
- NCT00928070
- Testing
- Fesoterodine
- Where
- 125 sites in United States
- Volunteers
- 566 people
- Sponsor
- Pfizer
Faecal Incontinence
A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment Period
The purpose of this study is to evaluate the safety, tolerability and efficacy of NRL001 in the treatment of faecal incontinence, compared against placebo
- Trial name
- NCT01656720
- Testing
- 1R, 2S-methoxamine hydrochloride
- Where
- 51 sites in Czechia, France and 7 more
- Volunteers
- 417 people
- Sponsor
- Norgine